Secretory PLA2-IIA: A new inflammatory factor for Alzheimer's disease

Journal of Neuroinflammation

Volumn 3, Issue , 2006, Pages

  Moses, Guna S D ^a   Jensen, Michael D ^b   Lue, Lin Fen ^a   Walker, Douglas G ^a   Sun, Albert Y ^b   Simonyi, Agnes ^b   Sun, Grace Y ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CYTOKINE; MESSENGER RNA; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 IIA; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; ENZYME INDUCTION; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; NERVE CELL LESION; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; UPREGULATION;

EID: 33750603049     PISSN: 17422094     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-3-28     Document Type: Article

References (60)

1. Silvestrelli G, Lanari A, Parnetti L, Tomassoni D, Amenta F: Treatment of Alzheimer's disease: From pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev 2006, 127(2)-148-157.
2. Jefferies WA, Food MR, Gabathuler R, Rothenberger S, Yamada T, Yasuhara O, McGeer PL: Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res 1996, 712(1):122-126.
3. Pike CJ, Cummings BJ, Cotman CW: Early association of reactive astrocytes with senile plaques in Alzheimer's disease. Exp Neurol 1995, 132(2):172-179.
4. Griffin WS: Inflammation and neurodegenerative diseases. Am J Clin Nutr 2006, 83(2):470S-474S.
5. Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ: Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brian Res 1998, 785(2):195-206.
6. McGeer EG, McGeer PL: Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(5):741-749.
7. Mrak RE, Griffin WS: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26(3):349-354.
8. Streit WJ: Microglia and Alzhelmer's disease pathogenesis. J Neurosci Res 2004, 77(1):1-8.
9. Walker DG, Lue LF: Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J Neurosci Res 2005, 81(3):412-425.
10. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21(3):383-421.
11. Akama KT, Albanese C, Pestell RG, Van Eldik LJ: Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci U S A 1998, 95(10):5795-5800.
12. Cacquevel M, Lebeurrier N, Cheenne S, Vivien D: Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 2004, 5(6):529-534.
13. Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE: Gene expression changes by amyloid (beta) peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 2006, 79(3):596-610.
14. Craft JM, Watterson DM, Van Eldik LJ: Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia 2006, 53(5):484-490.
15. Ranaivo HR, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, Watterson DM: Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 2006, 26(2):662-670.
16. Stuchbury G, Munch G: Alzheimer's associated inflammation, potential drug targets and future therapies. J Neural Transm 2005, 112(3):429-453.
17. Murakami M, Kudo I: Phospholipase A2. J Biochem (Tokyo) 2002, 131(3):285-292.
18. Bazan NG: Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor. J Lipid Res 2003, 44(12):2221-2233.
19. Bazan NG: Synaptic signaling by lipids in the life and death of neurons. Mol Neurobiol 2005, 31(1-3):219-230.
20. Adibhatla RM, Hatcher JF: Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radical Biol Med 2006, 40:376-387.
21. Balboa MA, Varela-Nieto I, Killermann Lucas K, Dennis EA: Expression and function of phospholipase A(2) in brain. FEBS Lett 2002, 531(1):12-17.
22. Farooqui AA, Yang HC, Rosenberger TA, Horrocks LA: Phospholipase A2 and its role in brain tissue. J Neurochem 1997, 69(3):889-901.
23. Sun GY, Xu J, Jensen MD, Siḿonyi A: Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 2004, 45(2):205-213.
24. Sun GY, Xu J, Jensen MD, Yu S, Wood WG, Gonzalez FA, Simonyi A, Sun AY, Weisman GA: Phospholipase A2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists. Mol Neurobiol 2005, 31(1-3):27-41.
25. Touqui L, Alaoui-El-Azher M: Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med 2001, 1(6):739-754.
26. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ: Gene expression profiling of 12633 genes in Alzheimer hippocampal CAl: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002, 70(3):462-473.
27. Stephenson D, Rash K, Smalstig B, Roberts E, Johnstone E, Sharp J, Panetta J, Little S, Kramer R, Clemens J: Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. Glia 1999, 27(2):110-128.
28. Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA: Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol Dis 1996, 3(1):51-63.
29. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P: Phospholipase A(2) in vascular disease. Circ Res 2001, 89(4):298-304.
30. Niessen HW, Krijnen PA, Visser CA, Meijer CJ, Erik Hack C: Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res 2003, 60(1):68-77.
31. Taketo MM, Sonoshita M: Phospolipase A2 and apoptosis. Biochim Biophys Acta 2002, 1585(2-3):72-76.
32. Valentin E, Lambeau G: Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins. Biochim Biophys Acta 2000, 1488(1-2):59-70.
33. Kennedy BP, Payette P, Mudgett J, Vadas P, Pruzanski W, Kwan M, Tang C, Rancourt DE, Cromlish WA: A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J Biol Chem 1995, 270(38):22378-22385.
34. Lin TN, Wang Q, Simonyi A, Chen JJ, Cheung WM, He YY, Xu J, Sun AY, Hsu CY, Sun GY: Induction of secretary phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain. J Neurochem 2004, 90(3):637-645.
35. Yagami T, Ueda K, Asakura K, Hata S, Kuroda T, Sakaeda T, Takasu N, Tanaka K, Gemba T, Hori Y: Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol Pharmacol 2002, 61(1):114-126.
36. Cunningham TJ, Souayah N, Jameson B, Mitchell J. Yao L: Systemic treatment of cerebral cortex lesions in rats with a new secreted phospholipase A2 inhibitor. J Neurotrauma 2004, 21(11):1683-1691.
37. Thwin MM, Ong WY, Fong CW, Sato K, Kodama K, Farooqui AA, Gopalakrishnakone P: Secretory phospholipase A2 activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum. Exp Brain Res 2003, 150(4):427-433.
38. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GMJ, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J: Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001, 35(1):72-79.
39. Xu J, Chalimoniuk M, Shu Y, Simonyi A, Sun AY, Gonzalez FA, Weisman GA, Wood WG, Sun GY: Prostaglandin E2 production in astrocytes: regulation by cytokines, extracellular ATP, and oxidative agents. Prostaglandins Leukot Essent Fatty Acids 2003, 69(6):437-448.
40. Walker DG, Lue LF, Beach TG: Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging 2001, 22(6):957-966.
41. Lue LF, Walker DG, Rogers J: Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 2001, 22(6):945-956.
42. Joachim CL, Morris JH, Selkoe DJ: Diffuse senile plaques occur commonly In the cerebellum in Alzheimer's disease. Am J Pathol 1989, 135(2):309-319.
43. Mrak RE, Sheng JG, Griffin WS: Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp Neurol 1996, 55(3):273-279.
44. Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC: Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 1998, 55(9):1185-1191.
45. Morris JC, Storandt M, McKeel DWJ, Rubin EH, Price JL, Grant EA, Berg L: Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996, 46(3):707-719.
46. Moynagh PN: The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat 2005, 207(3):265-269.
47. Samuelsson M, Fisher L, Iverfeldt K: beta-Amyloid and interleukin-1 beta induce persistent NF-kappaB activation in rat primary glial cells. Int J Mol Med 2005, 16(3):449-453.
48. Li W, Xia J, Sun GY: Cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC): response to genistein and pyrrolidine dithiocarbamate. J Interferon Cytokine Res 1999, 19(2):121-127.
49. Griffin WS, Mrak RE: Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol 2002, 72(2):233-238.
50. Wang G, Daniel BM, DeCoster MA: Role of nitric oxide in regulating secreted phospholipase A2 release from astrocytes. Neuroreport 2005, 16(12):1345-1350.
51. Shirai Y, Ito M: Specific differential expression of phospholipase A2 subtypes in rat cerebellum. J Neurocytol 2004, 33(3):297-307.
52. Kolko M, Christoffersen NR, Barreiro SG, Miller ML, Pizza AJ, Bazan NG: Characterization and location of secretory phospholipase A2 groups IIE, V, and X in the rat brain. J Neurosci Res 2006.
53. Macchioni L, Corazzi L, Nardicchi V, Mannucci R, Arcuri C, Porcellati S, Sposini T, Donato R, Goracci G: Rat brain cortex mitochondria release group II secretory phospholipase A(2) under reduced membrane potential. J Biol Chem 2004, 279(36):37860-37869.
54. Aarsman AJ, Neys FW, van der Helm HA, Kuypers FA, van den Bosch H: Sera of patients suffering from inflammatory diseases contain group IIA but not group V phospholipase A(2). Biochim Biophys Acta 2000, 1502(2):257-263.
55. Atsumi G, Murakami M, Tajima M, Shimbara S, Hara N. Kudo I: The perturbed membrane of cells undergoing apoptosis is susceptible to type II secretory phospholipase A2 to liberate arachidonic acid. Biochim Biophys Acta 1997, 1349(1):43-54.
56. Fourcade O, Le Balle F, Fauvel J, Simon MF, Chap H: Regulation of secretory type-II phospholipase A2 and of lysophosphatidic acid synthesis. Adv Enzyme Regul 1998, 38:99-107.
57. Nijmeijer R, Willemsen M, Meijer CJ, Visser CA, Verheijen RH, Gottlieb RA, Hack CE, Niessen HW: Type II secretory phospholipase A2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death. Am J Physiol Heart Circ Physiol 2003, 285(5):H2218-24.
58. Ikeno Y, Konno N, Cheon SH, Bolchi A, Ottonello S, Kitamoto K, Arioka M: Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor. J Biol Chem 2005, 280(30):28044-28052.
59. Kolko M, de Turco EB, Diemer NH, Bazan NG: Secretory phospholipase A2-mediated neuronal cell death involves glutamate ionotropic receptors. Neuroreport 2002, 13(15):1963-1966.
60. Yagami T, Ueda K, Sakaeda T, Itoh N, Sakaguchi G, Okamura N, Hori Y, Fujimoto M: Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol 2004, 67(6):1153-1165.